Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
17don MSN
From dismissed to finding confidence: What it's like living with a chronic, invisible illness
In 2010, at just 20 years old, Chelsea Ashe started losing vision in her left eye and developed severe double vision. Several doctors dismissed her concerns, suggesting she only needed glasses. "It ...
From this month, the cost of a 10-minute, six-monthly Ocrevus (ocrelizumab) subcutaneous injection for relapsing-remitting multiple sclerosis (MS) will be slashed from more than $16,500 to $31.60 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback